Comparison of the Effects of Levosimendan and Milrinone on B-Type Natriuretic Peptide and Major Cardiovascular Adverse Events in Patients with Acute Myocardial Infarction and Heart Failure
Objective To compare the effects of levosimendan and milrinone on B-type natriuretic peptide and major cardiovascular adverse events in patients with acute myocardial infarction(AMI)and heart failure(HF).Methods A total of 84 patients with AMI combined with HF admitted to the Jinxiang Conurty People's Hospital from May 2020 to May 2023 were selected as the research subjects.They were randomly divided into a control group and an observation group using a random number table method,with 42 cases in each group.The control group was treated with milrinone,while the observation group was treated with levosimendan.Compare the clinical efficacy,cardiac function indicators,serum B-type natriuretic peptide(BNP)levels,and major cardiovascular adverse events between two groups.Results The total effective rate of the observation group was 61.90%,higher than 33.33%of the control group,and the difference was statistically significant(P＜0.05).After treatment,the left ventricular ejection fraction in the observation group was higher than that in the control group,the left ventricular end systolic diameter and left ventricular end diastolic diameter were both shorter than those in the control group,the serum BNP level was lower than that in the control group,and the differences between the groups were statistically significant(P＜0.05).The incidence of major cardiovascular adverse events in the observation group was 7.14%,lower than 23.81%in the control group,and the difference was statistically significant(P＜0.05).Conclusion Compared to milrinone,the use of levosimendan in the treatment of AMI patients with HF is more effective,can effectively improve heart function,reduce serum BNP levels and the incidence of major cardiovascular adverse events,and is safer.
NETL
NSTL
万方数据
